Inflammation and T Lymphocyte Immunoregulation
炎症与T淋巴细胞免疫调节
基本信息
- 批准号:8268409
- 负责人:
- 金额:$ 30.21万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-08-01 至 2014-05-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Form Approved Through 11/30/2010 0MB No. 0925-0001
Department of Health and Human
Public Health Services 5 2006 PI: PARKER, DAVID C Council: 05/2009
12147749 Application 1 T32 AI078903-01 A1
\er length restrictions indicated. Dual:
1. TITLE OF PROJECT (Do not exceed 81 characters, including spaces and pun^ IRG: ZAI1 SRC(99) Received: 09/25/2008
Inflammation and T Lymphocyte Immunoregulation
2. RESPONSE TO SPECIFIC REQUEST FOR APPLICATIONS OR PROGRAM ANNOUNCEMENT OR SOLICITATION D NO | YES
(If "Yes," state number and title)
Number: PA-08-226 Title: Institutional Ruth L. Kirschstein NRSA
3. PROGRAM DIRECTOR/PRINCIPAL INVESTIGATOR New Investigator No DYOS
3a. NAME (Last, first, middle) 3b. DEGREE(S) 3h. eRA Commons User Name
Parker, David C. PhD PARKERD
3c. POSITION TITLE 3d. MAILING ADDRESS (Street, city, state, zip code)
Professor 3181 SW Sam Jackson Park Road
3e. DEPARTMENT, SERVICE, LABORATORY. OR EQUIVALENT Portland, Oregon 97239
Molecuir Microbiology & Immunolog
3f. MAJOR SUBDIVISION
School of Medicine
3g. TELEPHONE AND FAX (Area code, number and extension) E-MAIL ADDRESS:
TEL: 503-494-1498 FAX: 503-494-6862 parkerd@ohsu.edu
4. HUMAN SUBJECTS RESEARCH 4a. Research Exempt If "Yes," Exemption No.
D No S Yes S No D Yes
4b. Federal-Wide Assurance No. 4c. Clinical Trial 4d. NIH-defined Phase III Clinical Trial
FWA00000161 S No n Yes S No n Yes
5. VERTEBRATE ANIMALS Q No |3 Yes 5a. Animal Welfare Assurance No. A3304-01
6. DATES OF PROPOSED PERIOD OF COSTS REQUESTED FOR INITIAL 8. COSTS REQUESTED FOR PROPOSED
SUPPORT (month, day. year-MM/DD/YY) BUDGET PERIOD PERIOD OF SUPPORT
From Througli 7a. Direct Costs ($) 7b. Total Costs ($) 8a. Direct Costs ($) 8b. Total Costs ($)
07/01/2009 06/30/2014 $359,555 $379,020 $1,833,706 $1,931,031
9. APPLICANT ORGANIZATION 10. TYPE OF ORGANIZATION
Name Oregon Health & Science University Public: -^ n Federal ^ State Q Local
Address 3181 SW Sam Jackson Park Road Private: -^ d) Private Nonprofit
Portland, Oregon 97239 For-profit: -> L] General [j Small Business
I I Woman-owned O Socially and Economically Disadvantaged
11. ENTITY IDENTIFICATION NUMBER
1931176109A1
DUNS NO. 09-699-7515 Cong. District 1
12. ADMINISTRATIVE OFFICIAL TO BE NOTIFIED IF AWARD IS MADE 13. OFFICIAL SIGNING FOR APPLICANT ORGANIZATION
Name Valerie Mansur Name Deborah Golden-Eppelein
Title Assistant Manager Grants & Contracts Title Director, Grants & Contracts
Address 3181 SW Sam Jackson Park Road Address 3181 SW Sam Jackson Park Road
Portland, Oregon 97239 '^ Portland, Oregon 97239
Tel: 503-494-7784 FAX: 503-494-7787 Tel: 503-494-7784 FAX: 503-494-7787
E-Mail: orserv@ohsu.edu E-Mail: orserv@ohsu.edu
14. APPLICANT ORGANIZATION CERTIFICATION AND ACCEPTANCE: I certify that SIGNATURE OF OFFICIAL NAMED IN 13. DATE
the statements herein are true, complete and accurate to the best of my knowledge, and (In ink. "Per" signature not acceptable.)
accept the obligation to comply with Public Health Services terms and conditions If a grant
sistatewmarednetds aosr calariemssultmoafythsiusbajepcptlimcaetioton.crIimaminal,wcaivreil,tohrataadnmyinfaislstrea,tivfiectiptieonuasl,tioers.fraudulent AJ^J^ ¿y//^^'
PHS 398 (Rev. 11/07) Face Page Form Page 1
Program Director/Principal Investigator (Last, First, Middle): Parker, Davlci C.
Because of its interdisciplinary nature, its rapid acquisition and development of new technologies, and its
direct relevance to human disease, immunology is an excellent vehicle for training in basic biomedical
research. Exciting new findings and the enormous potential for powerful applications to human disease
continue to attract many of the best students to immunology. Increasingly, it is now possible to translate our
knowledge of immunity into manipulations of T cells and inflammation in clinical applications, and many of
the next generation of immunologists will find rewarding careers in translational research. We believe that
the best foundation for translational research is uncompromisingly rigorous traditional PhD training, with a
solid basic science basis. Scientists trained in this way have been responsible for past gains in knowledge
that are now being translated into clinical applications, and will continue to play this role in the future.
Nevertheless, we recognize that traditional PhD training can leave both a knowledge gap and a
misunderstanding of the culture of clinical medicine that many scientists find difficult to overcome. These
problems limit entry of some of the best PhD scientists into translational research. Our program incorporates
several innovative features designed to help our trainees bridge this gap. The twenty-one mentors in our
program lead an interactive, interdepartmental reseach community that covers the full range of biomedical
science from genomics and proteomics, intracellular signaling pathways, cell biology, microbiology, and
cellular immunology to clinical studies and trials, all centered around regulation of inflammation and T
lymphocyte biology. In our program, students and postdoctoral fellows studying areas as distinct as vaccine
design, immune evasion by viruses or bacteria, tumor immunology, immunopathology, transplantation, and
autoimmunity benefit from learning about methods of investigation and advances in the other areas as part
of this interactive research community. The goal of our program is to recruit talented and motivated students
and post-doctoral fellows, provide them with a firm foundation in the latest techniques and concepts in
biomedical research, expose them to translational research opportunities, and foster precision, curiosity,
daring, imagination, communication, and cooperation to give them the tools they need to direct independent
research programs and train the next generation of biomedical scientists.
Relevance: Many advances in treatment and prevention of human diseases depend upon advances in
understanding how the body works and interacts with the environment. This program is designed to train
effective biomedical scientists who will become leaders in making new discoveries and will remain alert to
the Dossibilities of usina new knowledge to improve human health
表格核准至2010年11月30日0MB编号0925-0001
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ann B Hill其他文献
Cytomegalovirus containing TRP2 antigen provides protective immunity against the poorly immunogenic B16BL6-D5 melanoma
- DOI:
10.1186/2051-1426-1-s1-p271 - 发表时间:
2013-11-01 - 期刊:
- 影响因子:10.600
- 作者:
Michael Neuberger;Shawn M Jensen;Guangwu Xu;Tameka Smith;Hong-Ming Hu;Ann B Hill;Carlo B Bifulco;Bernard A Fox - 通讯作者:
Bernard A Fox
Ann B Hill的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ann B Hill', 18)}}的其他基金
T cell response to fibroblast-trophic CMV vaccine in humans
人类 T 细胞对成纤维细胞营养型 CMV 疫苗的反应
- 批准号:
8973535 - 财政年份:2014
- 资助金额:
$ 30.21万 - 项目类别:
T cell response to fibroblast-trophic CMV vaccine in humans
人类 T 细胞对成纤维细胞营养型 CMV 疫苗的反应
- 批准号:
8839088 - 财政年份:2014
- 资助金额:
$ 30.21万 - 项目类别:
Cytomegalovirus and diseases of aging: a secondary analysis of NHANES III data
巨细胞病毒与衰老疾病:NHANES III 数据的二次分析
- 批准号:
8247692 - 财政年份:2011
- 资助金额:
$ 30.21万 - 项目类别:
Cytomegalovirus and diseases of aging: a secondary analysis of NHANES III data
巨细胞病毒与衰老疾病:NHANES III 数据的二次分析
- 批准号:
8095593 - 财政年份:2011
- 资助金额:
$ 30.21万 - 项目类别:
Exploiting the Unique T Cell Response to CMV for a Cancer Vaccine
利用 T 细胞对 CMV 的独特反应来开发癌症疫苗
- 批准号:
7796744 - 财政年份:2009
- 资助金额:
$ 30.21万 - 项目类别:
Exploiting the Unique T Cell Response to CMV for a Cancer Vaccine
利用 T 细胞对 CMV 的独特反应来开发癌症疫苗
- 批准号:
7742485 - 财政年份:2009
- 资助金额:
$ 30.21万 - 项目类别:
CD8 T Cell Response to Murine Cytomegalovirus
CD8 T 细胞对鼠巨细胞病毒的反应
- 批准号:
8698704 - 财政年份:2002
- 资助金额:
$ 30.21万 - 项目类别:
The CD8 T cell response to murine cytomegalovirus
CD8 T 细胞对鼠巨细胞病毒的反应
- 批准号:
7540954 - 财政年份:2002
- 资助金额:
$ 30.21万 - 项目类别:
MECHANISM OF MCMV's INHIBITION OF ANTIGEN PRESENTATION
MCMV抑制抗原呈递的机制
- 批准号:
7027644 - 财政年份:2002
- 资助金额:
$ 30.21万 - 项目类别:
相似海外基金
Targeting T lymphocyte potassium channels for the treatment of asthma--OLD
靶向T淋巴细胞钾通道治疗哮喘--OLD
- 批准号:
8122828 - 财政年份:2010
- 资助金额:
$ 30.21万 - 项目类别:
Establishment of the system to control T lymphocyte functions using Notch ligands
利用Notch配体控制T淋巴细胞功能的系统的建立
- 批准号:
18590474 - 财政年份:2006
- 资助金额:
$ 30.21万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
T Lymphocyte Apoptosis in Hepatitis C Persistence
丙型肝炎持续存在中的 T 淋巴细胞凋亡
- 批准号:
6778153 - 财政年份:2002
- 资助金额:
$ 30.21万 - 项目类别:
T Lymphocyte Apoptosis in Hepatitis C Persistence
丙型肝炎持续存在中的 T 淋巴细胞凋亡
- 批准号:
6929713 - 财政年份:2002
- 资助金额:
$ 30.21万 - 项目类别:
T Lymphocyte Apoptosis in Hepatitis C Persistence
丙型肝炎持续存在中的 T 淋巴细胞凋亡
- 批准号:
6544560 - 财政年份:2002
- 资助金额:
$ 30.21万 - 项目类别:
T Lymphocyte Apoptosis in Hepatitis C Persistence
丙型肝炎持续存在中的 T 淋巴细胞凋亡
- 批准号:
6615695 - 财政年份:2002
- 资助金额:
$ 30.21万 - 项目类别: